Poster presentations (as of 9/19/23)

**Poster Session B**  
**Friday, October 13 | 12:30 pm-4:00 pm**  
**Level 2, Exhibit Hall D**

B002: *Pharmacodynamics and antitumor mechanism of FHD-286 in a Phase 1 study in subjects with AML or MDS.* Mike Collins, Foghorn Therapeutics, Cambridge, MA United States.

B003: *Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer.* David J. Kwiatkowski, Brigham and Women’s Hospital, Boston, MA United States.

B004: *Molecular crosstalk between NF-κB and NRF2 signaling affects prognosis in HPV-associated head and neck cancer.* Aditi Kothari, UNC, Chapel Hill, NC United States.


B006: *High RAS-RAF binding as assessed via proximity ligation assay is associated with sensitivity to KRASG12C inhibitors in NSCLC.* Ryoji Kato, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL United States.

B007: *Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131).* Mohamed A. Gouda, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B008: *Machine-learning enabled quantification of colocalized multiplex IHC signals with spectral overlap.* Waleed Tahir, PathAI, Boston, MA United States.

B009: *A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.* Daniel Boiarsky, Tufts Medical Center, Boston, MA United States.

B010: *Spatially-resolved prediction of gene expression signatures in H&E whole slide images using additive multiple instance learning models.* Chintan Parmar, PathAI, Boston, MA United States.

B011: *GDF-15 is a biomarker of aggressiveness in epithelioid hemangioendothelioma and is down-regulated by sirolimus through ATF4 suppression.* Alessia Beretta, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

B012: *Validation of the OncoSignature assay, an ACR-368-tailored response-predictive quantitative multiplexed immunofluorescent assay for prediction of sensitivity to the CHK1/2 inhibitor ACR-368 in individual patients with cancer.* Michail Shipitsin, Acrivon Therapeutics, Watertown, MA United States.


B015: Tumor fraction as a predictive factor of outcome of patients referred for oncology early phase clinical trials: Analysis of the STING precision medicine study. Laila Belcaid, University of Copenhagen, Copenhagen, Denmark.

B016: AI analysis of histological images accurately identifies luminal subtype urothelial carcinomas characterized by high PPARG expression. Stefan Kirov, Flare Therapeutics, Boston, MA United States.

B017: Clinical Utility of Next Generation Sequencing in Advanced Colorectal Cancer: The Earlier The Better. Ho Jung An, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of.


B022: Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial. Brian Cunniff, University of Vermont, Burlington, VT United States.

B023: The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRAS$^{G12D}$ inhibition. Alison Smith, Kura Oncology, Inc., San Diego, CA United States.


B025: The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRAS$^{G12C}$ inhibitor adagrasib in KRAS$^{G12C}$ non-small cell lung carcinoma. Hetika V. Patel, Kura Oncology, San Diego, CA United States.

B026: Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer. Tej Tummala, Legorreta Cancer Center at Brown University, Providence, RI United States.


B028: Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-2/Bcl-XL inhibitors. Kirsi L. J. Toivanen, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

B029: Targeting phosphodiesterase: A potential strategy to treat LKB1-mutant cancers. Catherine Rono, Michigan Technological University, Houghton, MI United States.

B031: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors. Martin Wermke, TU Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany.
B032: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tricomplex RAS\textsuperscript{MULTI} (ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001. Alexander I. Spira, Virginia Cancer Specialists, NEXT Oncology Virginia, Fairfax, VA United States.


B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). Ecaterina E. Dumbrava, MD Anderson Cancer Center, Houston, TX United States.

B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. Benjamin Schlechter, Dana Farber Cancer Institute, Boston, MA United States.

B037: A pharmacodynamic pilot study of DS8201a in patients with HER2 expressing advanced solid tumors. Alice Chen, Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD United States.

B038: Clinical and Biological Activity of ST101, a Peptide Antagonist of C/EBPβ, in Recurrent Glioblastoma (rGBM) Patients. Results From the rGBM Cohort of a Multi-Cohort Phase 2 Study. Fabio Iwamoto, Columbia University, New York, NY United States.

B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111 / DEP irinotecan) in patients with advanced solid tumours. Jia Liu, The Kinghorn Cancer Centre, St Vincent’s Hospital; Garvan Institute of Medical Research; St Vincent’s Clinical School, University of New South Wales, Sydney, Australia.

B040: NCI 10129: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors. Michael Cecchini, Yale University School of Medicine, New Haven, CT United States.

B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of Module 1 Dose Escalation. Elizabeth K. Lee, Dana-Farber Cancer Institute, Boston, MA United States.


B043: Preliminary results from a phase I/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. Elena Garralda, Hospital Universitari Vall D’Hebron, Barcelona, Spain.

B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors. Simon Rodney, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.

B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations:
Preclinical and Phase 1b results. Ezra Rosen, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY United States.

B046: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study. Christophe Le Tourneau, Department of Drug Development and Innovation, Institut Curie, Paris, France.

B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies. Nebojsa Skorupan, National Cancer Institute, Center for Cancer Research, Bethesda, MD United States.

B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302). Khurum Khan, University College London Hospital, London, United Kingdom.

B049: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323). Richard H. Wilson, Beatson West of Scotland Cancer Centre/University of Glasgow, Glasgow, United Kingdom.

B051: PARG inhibition leads to the formation of toxic nuclear PARP1 aggregates. Sateja Paradkar, Yale University, New Haven, CT United States.

B052: Small molecule RPA inhibitors abrogate the ATR kinase signaling pathway. Matthew R. Jordan, Indiana University School of Medicine, Indianapolis, IN United States.


B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair. Antoine Simoneau, Tango Therapeutics, Boston, MA United States.


B056: Modulation of the DNA replication stress response and chemo-response by the mono-ADP-ribosyltransferase PARP14. Ashna Dhoonmoon, Penn State College of Medicine, Hershey, PA United States.

B057: Preclinical development of PKMYT1 and ATR inhibitor combinations. Michal Zimmermann, Repare Therapeutics, St. Laurent, QC Canada.

B058: Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer. Mark Albertella, AstraZeneca, Cambridge, United Kingdom.

B059: Identification of Cohesin RAD21 as a Novel Aneuploidy-Associated Marker Driving Prostate Cancer Progression by Mitigating Toxic DNA Damage. Xiaofeng A. Su, Center for Prostate Disease Research, Bethesda, MD United States.
B060: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer. Haineng Xu, University of Pennsylvania, Philadelphia, PA United States.


B062: Loss of MED12 activates the TGFβ pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells. Lindsey M. Pale, Penn State College of Medicine, Hershey, PA United States.

B063: Proteasome Inhibitors Induce DNA Damage and Mitotic Catastrophe in Acute Lymphoblastic Leukaemia (ALL) via Autophagy-mediated Degradation of WEE1. Chun-fung Sin, University of Hong Kong, Hong Kong, Hong Kong (Greater China).


B065: Enhancing the therapeutic gain of proton radiotherapy in Locally Advanced Rectal Cancer (LARC) through manipulation of WSB1, ATM, and β-Catenin/c-Myc pathway Ubiquitination. Cameron M. Callaghan, Mayo Clinic, Rochester, MN United States.

B066: FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. Junjie Chen, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B067: Modulation of the DNA damage response by novel Ku-DNA binding inhibitors enhances cellular effects of DNA-double strand break inducing agents. Pamela L. Mendoza-Munoz, Indiana University, School of Medicine, Indianapolis, IN United States.

B068: Targeting vulnerabilities in double strand break repair in cancer with polymerase theta inhibitors. Katelyn Noronha, Yale University, New Haven, CT United States.

B069: Antitumor effect of AZD5305, a selective PARP1 inhibitor, in breast and gastric cancer cells. Sujin Ham, Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of.


B076: Discovery of BBT-176 as Fourth Generation EGFR Tyrosine Kinase Inhibitor. Krishna Babu Duggirala, Korea Research Institute of Chemical Technology, Daejeon, Korea, Republic of.


B079: Molecular determinants of sensitivity to Polatuzumab-Vedotin. Sean R. Corcoran, National Cancer Institute, Bethesda, MD United States.

B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer. Chendi Li, Massachusetts General Hospital/Harvard Medical School, Boston, MA United States.

B081: Aurora kinase A inhibition overcomes adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer. Chendi Li, Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA United States.


B083: Secondary KRAS mutations lead to acquired resistance to KRASG12D inhibitor in colorectal cancer. Simone Lieb, Boehringer Ingelheim RCV, Wien, Austria.

B084: Sotorasib/SHP2 inhibitors combo, KRAS\(^{G12C}(ON)I\) and RAS\(^{MULT}(ON)I\) effectively target KRAS\(^{G12C}\) tumors developing secondary resistance to Sotorasib via KRAS\(^{G12C}\) amplification. Hitendra S. Solanki, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL United States.

B085: Beyond endocrine resistance: Estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer. Marwa Taya, Tel Aviv University, Tel Aviv, Israel.


B087: CTNNB1 mutations can mediate resistance to EGFR targeted therapies in Non-Small Cell Lung Cancer. Anurima Majumder, Moffitt Cancer Center, Tampa, FL United States.

B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and PI3K/AKT/mTOR pathways. Tracy T. Tang, Vivace Therapeutics, San Mateo, CA United States.

B089: MUC1-C is a common driver of acquired osimertinib resistance in NSCLC. Naoki Haratake, Dana-Farber Cancer Institute, Boston, MA United States.

B090: Partially open conformation of the G323E mutated HIF-2α PASB domain captured by X-ray crystallography. Steven Shia, Arcus Biosciences, Hayward, CA United States.

B091: Overexpression of Muscleblind Like Splicing Regulator 2 (MBNL2) Enhances Cisplatin Resistance in Ovarian Cancer. Woong Ju, Ewha Womans University, Seoul, Korea, Republic of.

B093: Treating KRAS(G12D) inhibitor resistance using a KRAS- and HSP90 chaperone-targeted hetero-bispecific small molecule agent. Ines Pulido, University of Illinois Chicago, Chicago, IL United States.

B094: Pentraxin 3 promotes the therapy resistance to sorafenib via regulating apoptosis in hepatocellular carcinoma. Ping-Wen Chen, National Cheng Kung University, Tainan City, Taiwan (Greater China).


B096: A comparative assessment of selinexor with trabectedin or lurbinectedin in patient-derived xenografts (PDX) of dedifferentiated liposarcoma (DDLPS) highlights the effectiveness of their sequential or concomitant combination. Sandro Pasquali, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.


B100: Charting the transcriptomic landscape of primary and metastatic cancers in relation to their origin and target normal tissues. Neel Sanghvi, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD United States.

B101: A phenotypic drug screen identifies a targetable metabolic vulnerability in brain metastases. Agata M. Kieliszek, McMaster University, Hamilton, ON Canada.

B102: Predicting small cell lung cancer liver metastasis. George Chrisafis, National Cancer Institute, Bethesda, MD United States.


B104: U18666A-induced cholesterol accumulation decreases tumor-derived exosomes load and modulates malignant transformation. Syed Sultan Beevi, KIMS Foundation and Research Centre, Hyderabad, India.

B105: Antineoplastic effects and expression modulations in proliferation/apoptosis related genes by riproximin in breast cancer cells. Asim Pervaiz, Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan.

B106: Discovery of Covalent NRAS Inhibitors Targeting the Palmitoylation Site through Imaging-Based High-Throughput Screening. Zhao Wang, Covant Therapeutics, Boston, MA United States.

B107: Determining the Mechanism of Action of the Anti-ENTPD2 Antibody, KAZ954. Samantha Zaharevitz, Novartis Institutes for BioMedical Research, San Diego, CA United States.
B108: NUDT5 inhibition differentially affects IDH1-Wildtype and Mutant high-grade glioma to induce NAD+ independent radiosensitization and anti-proliferative effects. Thomas J.R. Cox, University of Surrey, Guildford, United Kingdom.

B109: MTHFD1/2 inhibitor TH9619 targets the DNA damage response and causes cancer-specific folate trapping with an unprecedented therapeutic window. Thomas Helleday, Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

B110: β3-adrenergic receptor as a new molecular target in neuroblastoma treatment. Rossana Putino, Meyer Children Hospital, Florence, Italy.

B112: SNAP23-dependent SNARE complex is a novel molecular target in AL Amyloidosis and Multiple Myeloma by blocking free light chain secretion and triggering a terminal unfolded protein response. Emre Karayol, Brigham and Women’s Hospital, Boston, MA United States.

B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers. Koichi Ito, Prelude Therapeutics Inc., Wilmington, DE United States.

B114: A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies. Devalingam Mahalingam, Northwestern University Feinberg School of Medicine, Chicago, IL United States.

B115: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor. Chandrasekar Iyer, Loxo@Lilly, Indianapolis, IN United States.


B121: CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic. Agnieszka Bojko-Matuszek, Celon Pharma S.A., Preclinical Development Department, Kazuń Nowy, Poland.


B124: MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression. William C. Comb, Mythic Therapeutics, Waltham, MA United States.


B126: Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Timothy P. DiPeri, MD Anderson Cancer Center, Houston, TX United States.


B129: A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models. Yan Yang, Regeneron Pharmaceuticals, Tarrytown, NY United States.

B130: Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor2 (HER2)-positive Solid Cancers. Do-Youn Oh, Seoul National University Hospital, Seoul, Korea, Republic of.

B131: NXC03, an AI-designed, affinity-attenuated IL-21 mutein with half-life extension enhances antitumor immunity. Taylor B. Guo, neoX Biotech, Shanghai, China (Mainland).

B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone. Michelle Haber, Children’s Cancer Institute, Sydney, Australia.


B136: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability. Marta Cortes-Cros, Novartis Institutes for BioMedical Research, Basel, Switzerland.

B137: Selective inhibition of the active state of KRAS<sup>G12V</sup> with the non-covalent, tri-complex inhibitor RM-048. Bianca J. Lee, Revolution Medicines, Redwood City, CA United States.

B139: Cancer-specific AI identifies multi-modal biomarkers of therapeutic response for 1,951 drugs including TNG348, a highly selective USP1 inhibitor. Adam Yaari, Serinus Biosciences Inc, New York, NY United States.

B140: Elucidating the novel mechanism of action of VVD-065, an allosteric molecular glue for the KEAP1-CUL3 E3-ligase complex that promotes NRF2 degradation in NRF2-activated cancers. Aaron Snead, Vividion Therapeutics, San Diego, CA United States.


B143: HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MS<sup>high</sup> models. Stephane Ferretti, Novartis Institutes for Biomedical Research Oncology Research, Basel, Switzerland.

B144: Discovery and preclinical evaluation of novel oral WEE1 degraders. Yang Xie, neoX Biotech, Boston, MA United States.


B146: Design and preclinical evaluation of CPL976-MMAE - novel, potent AXL-PD-L1 bispecific antibody conjugated with MMAE in targeted anticancer therapy. Defina Popiel, Celon Pharma S.A., Preclinical Development Department, Kazuń Nowy, Poland.

B147: Preclinical evaluation of XPO1 inhibition with topoisomerase-I (topo-I) inhibition in colorectal cancer (CRC) cell lines and patient-derived xenograft (PDX) models. Robert W. Lentz, University of Colorado School of Medicine, Aurora, CO United States.

B148: Novel Low-Atomic Cluster Ag5 Induced Oxidative Stress And Antiproliferation In Esophageal Squamous Cell Carcinoma Cells. Akihiro Ohashi, National Cancer Center, Kashiwa, Japan.


B151: Discovery and characterization of a novel small molecule brain penetrant PD-L1 inhibitor. Haiyan Ying, Abbisko Therapeutics, Shanghai, China (Mainland).
B152: Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis. Xiuning Le, Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B153: Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations. Xiuning Le, MD Anderson Cancer Center, Houston, TX United States.


B156: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1. Timothy A. Yap, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B157: Preclinical evaluation of the blood-brain barrier permeability and intracranial efficacy of the next-generation RET inhibitor Vepafestinib. Igor Odintsov, Brigham and Women's Hospital, Harvard Medical School, Boston, MA United States.

B159: A First-In-Human Study of CDK9 Inhibitor KB-0742 Demonstrates Evidence of Tolerability and Clinical Activity. Miguel Villalona-Calero, City of Hope, Duarte, CA United States.


B164: ASTX029 is a dual mechanism ERK1/2 inhibitor with activity in models of MAPK-inhibitor resistance. Joanne Munck, Astex Pharmaceuticals, Cambridge, United Kingdom.

B165: A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3Kδ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models. Francesco Bertoni, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.


B168: Identification of STX-241, a CNS-penetrant and mutant-selective EGFR inhibitor with activity on osimertinib-resistant C797x mutations. Raymond A. Pagliarini, Scorpion Therapeutics, Boston, MA United States.
B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring CCNE1 amplification and/or deleterious alterations in FBXW7 or PPP2. Elia Aguado-Fraile, Repare Therapeutics, Cambridge, MA United States.

B170: The in vitro anti-tumor activity of the multi-kinase inhibitor nemtabrutinib (ARQ-531, MK-1026) is seen across multiple B-cell lymphoma subtypes, only partially overlapping with what achieved by single BTK inhibition. Giulio Sartori, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

B171: BX-795 enhances the efficacy of crizotinib in colorectal cancer cells by altering the activity of aurora kinases. Rajat Bhattacharya, The University of Texas M.D. Anderson Cancer Center, Houston, TX United States.

B172: Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor. Susanta Samajdar, Aurigene Oncology Limited, Bangalore, India.


B175: In-vitro Multicellular 3D-Spheroid Model Demonstrates the Synergistic Effect of 2-Domain Soluble FMS-Like Tyrosine Kinase-1 (2d-sFlt-1) for Breast Cancer Targeted Therapies. Adel Zaid I. Mutahar, Molecular Oncology Lab., Department of Studies in Biotechnology, University of Mysore, Mysore, India.


B178: Proteomics platform identifies vulnerabilities for specific DNA damage repair drugs. Gali Arad, Protai Bio, Tel Aviv, Israel.

B179: 2-Deoxy-D-glucose (2-DG) combination with ketogenic diet induces sedation and hypothermia in mice that becomes lethal. Rafal Zielinski, UT. MD Anderson Cancer Center, Houston, TX United States.